The drugmaker, along with its partner Eisai, published an open letter to CMS about the coverage proposal Feb. 10. Under the current proposal, Medicare would only cover Aduhelm for patients in clinical trials, a move that would deny “almost all Medicare beneficiaries access to Aduhelm — the only FDA-approved treatment for Alzheimer’s disease in nearly 20 years,” Priya Singhal, MD, Biogen’s head of research and development, wrote in the letter.
The restriction would also significantly limit and delay coverage for Aduhelm and future similar drugs and create a “major burden for providers, patients and CMS,” Dr. Singhal added.
The drugmaker asked CMS to reverse its position and expand coverage of Aduhelm in accordance with its FDA-approved indications.
CMS is set to issue a final determination on Aduhelm coverage April 11.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
